Goncalves Cabecinhas Ana Rita, Roloff Tim, Stange Madlen, Bertelli Claire, Huber Michael, Ramette Alban, Chen Chaoran, Nadeau Sarah, Gerth Yannick, Yerly Sabine, Opota Onya, Pillonel Trestan, Schuster Tobias, Metzger Cesar M J A, Sieber Jonas, Bel Michael, Wohlwend Nadia, Baumann Christian, Koch Michel C, Bittel Pascal, Leuzinger Karoline, Brunner Myrta, Suter-Riniker Franziska, Berlinger Livia, Søgaard Kirstine K, Beckmann Christiane, Noppen Christoph, Redondo Maurice, Steffen Ingrid, Seth-Smith Helena M B, Mari Alfredo, Lienhard Reto, Risch Martin, Nolte Oliver, Eckerle Isabella, Martinetti Lucchini Gladys, Hodcroft Emma B, Neher Richard A, Stadler Tanja, Hirsch Hans H, Leib Stephen L, Risch Lorenz, Kaiser Laurent, Trkola Alexandra, Greub Gilbert, Egli Adrian
Laboratory of Virology, University Hospital Geneva, 1205 Geneva, Switzerland.
Center for Emerging Viral Diseases, University Hospital Geneva, 1205 Geneva, Switzerland.
Microorganisms. 2021 Mar 25;9(4):677. doi: 10.3390/microorganisms9040677.
The rapid spread of the SARS-CoV-2 lineages B.1.1.7 (N501Y.V1) throughout the UK, B.1.351 (N501Y.V2) in South Africa, and P.1 (B.1.1.28.1; N501Y.V3) in Brazil has led to the definition of variants of concern (VoCs) and recommendations for lineage specific surveillance. In Switzerland, during the last weeks of December 2020, we established a nationwide screening protocol across multiple laboratories, focusing first on epidemiological and microbiological definitions. In January 2021, we validated and implemented an N501Y-specific PCR to rapidly screen for VoCs, which are then confirmed using amplicon sequencing or whole genome sequencing (WGS). A total of 13,387 VoCs have been identified since the detection of the first Swiss case in October 2020, with 4194 being B.1.1.7, 172 B.1.351, and 7 P.1. The remaining 9014 cases of VoCs have been described without further lineage specification. Overall, all diagnostic centers reported a rapid increase of the percentage of detected VOCs, with a range of 6 to 46% between 25 to 31 of January 2021 increasing towards 41 to 82% between 22 to 28 of February. A total of 739 N501Y positive genomes were analysed and show a broad range of introduction events to Switzerland. In this paper, we describe the nationwide coordination and implementation process across laboratories, public health institutions, and researchers, the first results of our N501Y-specific variant screening, and the phylogenetic analysis of all available WGS data in Switzerland, that together identified the early introduction events and subsequent community spreading of the VoCs.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)谱系B.1.1.7(N501Y.V1)在英国迅速传播,B.1.351(N501Y.V2)在南非迅速传播,P.1(B.1.1.28.1;N501Y.V3)在巴西迅速传播,这导致了关注变异株(VoC)的定义以及针对特定谱系监测的建议。在瑞士,2020年12月的最后几周,我们在多个实验室建立了一项全国性筛查方案,首先侧重于流行病学和微生物学定义。2021年1月,我们验证并实施了一项针对N501Y的聚合酶链反应(PCR),以快速筛查关注变异株,然后使用扩增子测序或全基因组测序(WGS)进行确认。自2020年10月检测到首例瑞士病例以来,共识别出13387例关注变异株,其中4194例为B.1.1.7,172例为B.1.351,7例为P.1。其余9014例关注变异株病例未进一步明确谱系。总体而言,所有诊断中心报告检测到的关注变异株百分比迅速上升,在2021年1月25日至31日期间为6%至46%,在2月22日至28日期间升至41%至82%。共分析了739个N501Y阳性基因组,结果显示多种引入瑞士的事件。在本文中,我们描述了跨实验室、公共卫生机构和研究人员的全国协调与实施过程、我们针对N501Y的变异株筛查的初步结果,以及对瑞士所有可用全基因组测序数据的系统发育分析,这些共同确定了关注变异株的早期引入事件及随后在社区中的传播情况。